Work

Exceptional response to Pembrolizumab, Olaparib, and intrathecal Nivolumab in refractory Stage IV Melanoma

Year: 2025

Type: article

Abstract: Background: In advanced melanoma, treatment options remain very limited in patients with leptomeningeal disease and brain metastases. Here, we report a case of a 40-year-old female patient with BRAF V600E-mutated, stage IV cutaneous melanoma demonstrating rapid and significant clinical and radiological benefit under a novel therapeutic strategy combining pembrolizumab (PD-1 inhibition), olaparib (PARP inhibitor), and intrathecal nivolumab.

Source: EJC Skin Cancer

DOI: 10.1016/j.ejcskn.2025.100630

Authors: G. Tassopoulos, B. Schilling

Institution: University Hospital Frankfurt

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,340